CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The CCTG Annual Spring Meeting is only 7 weeks away!
If you have received an invitation, please register and book your hotel accommodation as soon as possible and no later than March 16.
The CCTG IND Program has launched the Early Clinical Trials Educational Series, a virtual education workshop series that offers topics of relevance and interest to early drug trial investigation. The series curriculum covers early clinical trial design and conduct, planning correlative analyses, data interpretation and publication of results, as well as operational considerations and policy and regulatory framework.
Congratulations to Dr Marie Plante and the entire CX5 team on receiving the 2025 International Journal of Gynecological Cancer (IJGC) Award for the Most Downloaded Article for the CX5 substudy: Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. The IJGC has recognized the CX5 sub study as the one of the top-performing articles based on 2025 download data.
The new SC30 RATIONAL-PT international study is now open in Canada and will compare different approaches to preventing infections in people with blood cancers with low antibody levels. People with blood cancers often develop low levels of antibodies that can lead to an increased chance of developing an infection. These infections can cause serious illness, which may require being admitted to hospital.
Funded invitations to the CCTG Annual Spring Meeting of Participants have been sent!
Trial-specific DSMC Summary Reports are now posted on trial webpages. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
